A proof-of-mechanism trial in asthma with lunsekimig, a bispecific nanobody(R) molecule. Deiteren A, Krupka E, Bontinck L, Imberdis K, et al. Eur Respir J 2025 Jan 30:2401461. doi: 10.1183/13993003.01461-2024.

Read + Share

Amedeo Smart

Independent Medical Education

Deiteren A, Krupka E, Bontinck L, Imberdis K, et al. A proof-of-mechanism trial in asthma with lunsekimig, a bispecific nanobody(R) molecule. Eur Respir J 2025 Jan 30:2401461. doi: 10.1183/13993003.01461-2024.
PMID: 39884759